Keyword: Genzyme

Sanofi has been among those hardest hit by diabetes pressure, and now, competition is hurting the prized asset from its $11.6 billion Bioverativ buy.

When Sanofi inked a massive lease in Cambridge Crossing last year, the drugmaker found itself in prime position for another real estate deal.

Sanofi just won FDA approval for Cablivi, acquired in its $4.5 billion Ablynx deal and expected to peak at $500 million in sales.

Sanofi has picked the spot for its Massachusetts HQ, once again planting its flag squarely in the epicenter of biotech on the East Coast.

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

Genzyme is reportedly looking for 400,000 square feet of space near its headquarters, hoping to gather scattered operations and secure room to grow.

Analysts previously predicted Cablivi (caplacizumab) could be the standard of care for aTTP, with peak global sales at $500 million.

Sanofi offered a confidential discount as part of a process to secure coverage for Dupixent in the U.K.

The decision by two leading pharmacy benefit managers to exclude Sanofi's big-sellers in diabetes took a toll in 2017.

Sanofi finally scored a deal. It plans to shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.